Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01803438

Recruitment Status : Completed

First Posted : March 4, 2013

Last Update Posted : February 25, 2020

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Medtronic Atrial Fibrillation Solutions

Information provided by (Responsible Party):

Medtronic Cardiac Rhythm and Heart Failure

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	October 16, 2019
Actual Study Completion Date :	January 20, 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Pavlovic N, Chierchia GB, Velagic V, Hermida JS, Healey S, Arena G, Badenco N, Meyer C, Chen J, Iacopino S, Anselme F, Dekker L, Scazzuso F, Packer DL, de Asmundis C, Pitschner HF, Piazza FD, Kaplon RE, Kuniss M; Cryo-FIRST Investigators. Initial rhythm control with cryoballoon ablation vs drug therapy: Impact on quality of life and symptoms. Am Heart J. 2021 Dec;242:103-114. doi: 10.1016/j.ahj.2021.08.007. Epub 2021 Sep 8.

To Top